Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)

Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Cognitive Post-acute Sequelae of COVID-19 (PASC)

NCT05092516•Massachusetts General Hospital

View on ClinicalTrials.gov

Summary

The main goal of this study is to improve dysexecutive symptoms (e.g., sustained attention, processing speed) in patients exhibiting post-acute sequelae of COVID-19 (PASC) through home-based transcranial direct current stimulation (tDCS), a noninvasive method that uses low intensity electric currents delivered to the brain through stimulation electrodes on the scalp.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Ability to provide informed consent
•A diagnosis of PASC as indicated by past COVID-19 infection, and persistent symptoms, including 'brain fog', confusion, short-term memory deficits, trouble concentrating, delirium, difficulties in multitasking.

Exclusion Criteria

•History of epilepsy
•Metallic implants in the head and neck,
•Brain stimulators
•Pacemakers
•Pregnancy
•Active substance dependence (except for tobacco)
•Premorbid major neurological illness
•Severe mental illness (e.g., bipolar disorder, schizophrenia)
•Attention Deficit Hyperactivity Disorder

Locations (1)

Massachusetts General Hospital

Charlestown, Massachusetts, United States

Key Dates

Start Date

June 7, 2022

Primary Completion Date

March 13, 2025

Completion Date

June 15, 2026

Last Updated

November 10, 2025

Enrollment

ESTIMATED participants

Conditions

Dysexecutive SyndromePost-Acute Sequelae of COVID-19

Interventions

Active tDCS

DEVICE

Sham tDCS

DEVICE